Skip to search formSkip to main contentSkip to account menu

XELIRI Regimen

Known as: Capecitabine/Irinotecan Regimen, CapIri, XelIri 
A chemotherapy regimen containing capecitabine and irinotecan used in the treatment of colorectal, esophageal and gastric cancer.
National Institutes of Health

Related topics

Related topics

2 relations
Irinotecan hydrochloridecapecitabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial
Background There has been little progress toward personalized therapy for patients with metastatic colorectal cancer (mCRC). TYMS… 
2012
2012
Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: A retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal…
Abstract Background. Metastatic colorectal cancer (CRC) is predominantly a disease of the elderly, therefore the current… 
2011
2011
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
This retrospective study investigated the clinical characteristics of patients with metastatic colorectal cancer (mCRC) depending… 
2010
2010
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
BACKGROUND More than half of patients with pancreatic adenocarcinoma (PA) are candidates for further treatment when they… 
Highly Cited
2008
Highly Cited
2008
Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of…
4030 Background: The combination of Bev with 5-FU/FA and irinotecan or oxaliplatin is highly active in ACRC. A recent phase III… 
2008
2008
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group
A Valine residue at position 105 of the GSTP1 protein results in decreased enzyme activity. As nuclear GSTP1 activity decreases… 
2007
2007
Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II…
4034 Background: Bevacizumab (Bev) combined with 5-FU/FA and both, irinotecan or oxaliplatin are standard regimens for mCRC… 
2005
2005
Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer (CRC). Long-term results of the prospective multicenter EORTC phase III…
3577 Background: Oral fluoropyrimidines in combination with irinotecan may be an alternative to infusional 5-FU/FA+irinotecan… 
2005
2005
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
Capecitabine is a highly active oral fluoropyrimidine that is an attractive alternative to 5-fluorouracil in colorectal cancer… 
2004
2004
Capecitabine/ irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination…
3534 Background: Previously, we reported the interim results of a randomized phase II trial with CapIri vs CapOx as first-line… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)